Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relapsing-remitting

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    297 result(s) found for: Relapsing-remitting. Displaying page 6 of 15.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2009-016824-29 Sponsor Protocol Number: 1232009 Start Date*: 2010-04-06
    Sponsor Name:Dansk Multipel Sclerose Center
    Full Title: REsPons på interferon-Alfa hos InterfeRon-β-neutraliserende antistof-positive patienter med multipel sklerose
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013695-46 Sponsor Protocol Number: 701068-524 Start Date*: 2009-10-22
    Sponsor Name:MERCK SERONO s.a.s
    Full Title: ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQU...
    Medical condition: Sclérose en plaques récurrente (SEP-R)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-011523-31 Sponsor Protocol Number: 09/H0720/64 Start Date*: 2009-06-23
    Sponsor Name:R & D, Cambridge University Hospitals
    Full Title: A study of the immune response to vaccination in MS patients treated with alemtuzumab
    Medical condition: The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    9.1 10063400 Secondary progressive multiple sclerosis PT
    9.1 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004807-10 Sponsor Protocol Number: inims-004 Start Date*: 2013-07-17
    Sponsor Name:University Medical Center Hamburg Eppendorf
    Full Title: Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuri...
    Medical condition: MS patients who suffer from severe Optic Neuritis without satisfying improvement after treatment with steroids (3-5 days with 1 g daily at least 7 days prior to randomization) and with persisting v...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10070425 Multiple sclerosis exacerbation LLT
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005021-11 Sponsor Protocol Number: 28851 Start Date*: 2009-10-14
    Sponsor Name:Merck Serono SA - Geneva, An affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-018084-27 Sponsor Protocol Number: MS-GA-301 Start Date*: 2010-03-30
    Sponsor Name:Teva Pharmaceutical Industries, Ltd.
    Full Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer...
    Medical condition: Relapsing-remitting Multiple Sclerosis (RR MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) EE (Completed) CZ (Completed) LT (Completed) BG (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005624-98 Sponsor Protocol Number: 109MS309 Start Date*: 2015-09-09
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms o...
    Medical condition: Relapsing-Remitting Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) EE (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004819-12 Sponsor Protocol Number: FullResponders Start Date*: 2018-01-10
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients: a multicentre randomized clinical trial.
    Medical condition: Relapsing-Remitting multiple sclerosis (RR-MS),
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023023-19 Sponsor Protocol Number: CFTY720DIT01 Start Date*: 2010-12-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000499-25 Sponsor Protocol Number: 28733 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck Serono International S.A.
    Full Title: International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in multidose cartridges in patien...
    Medical condition: Relapsing forms of Multiple Sclerosis (RMS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008719-25 Sponsor Protocol Number: CBAF312A2201 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determi...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-024000-10 Sponsor Protocol Number: 101MS206 Start Date*: 2011-06-28
    Sponsor Name:Biogen Idec Limited
    Full Title: A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000801-28 Sponsor Protocol Number: MSB-IG-H-2101 Start Date*: 2023-07-24
    Sponsor Name:Cellerys AG
    Full Title: Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004736-79 Sponsor Protocol Number: 1102-CT02 Start Date*: 2007-03-06
    Sponsor Name:Antisense Therapeutics Ltd.
    Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous inje...
    Medical condition: To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001692-39 Sponsor Protocol Number: CFTY720DDE06 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS pa...
    Medical condition: Multiple Sclerosis Depression
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001486-17 Sponsor Protocol Number: 109MS407 Start Date*: 2014-05-06
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects with Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE)
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003577-63 Sponsor Protocol Number: DYNAMICS_Study Start Date*: 2022-04-06
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsing-remitting multiple sclerosis: correlation with disease activity, cognition, fatigue, depression and quality o...
    Medical condition: Multiple sclerosis patients in relapse and remission form
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003282-29 Sponsor Protocol Number: 109MS311 Start Date*: 2016-06-17
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-004903-39 Sponsor Protocol Number: WCNNMBJR001 Start Date*: 2005-07-26
    Sponsor Name:The Walton Centre for Neurology and Neurosurgery
    Full Title: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.
    Medical condition: Early, active relapsing remitting Multiple Sclerosis (RRMS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 11 03:43:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA